Get the Stockscreener App
16.64
1.37%
0.2249
Evolus Inc stock is traded at $16.64, with a volume of 70,080.
It is up +1.37% in the last 24 hours and up +1.87% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$16.42
Open:
$16.4
24h Volume:
70,080
Relative Volume:
0.13
Market Cap:
$1.04B
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-14.23
EPS:
-1.17
Net Cash Flow:
$-35.64M
1W Performance:
-0.27%
1M Performance:
+1.87%
6M Performance:
+25.15%
1Y Performance:
+109.90%
1-Day Range:
$16.27
$16.65
1-Week Range:
$15.95
$16.98
52-Week Range:
$7.74
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report
Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian
Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat
Objective long/short (EOLS) Report - Stock Traders Daily
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com
Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch
Evolus gains EU certification for new dermal filler products - Investing.com
Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - StockTitan
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - MSN
Evolus (EOLS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - StockTitan
Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 25 - GuruFocus.com
Evolus to Report Third Quarter Financial Results on November 6, 2024 - Business Wire
First Week of December 20th Options Trading For Evolus (EOLS) - Nasdaq
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet? - Simply Wall St
When the Price of (EOLS) Talks, People Listen - Stock Traders Daily
Evolus (NASDAQ:EOLS) Shares Down 6.2%Here's Why - MarketBeat
Evolus Inc (EOLS) Stock Price Down 4.81% on Oct 17 - GuruFocus.com
Evolus Inc (EOLS) receives an Overweight rating from Barclays - Knox Daily
SG Americas Securities LLC Makes New $623,000 Investment in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Hits New 1-Year HighTime to Buy? - MarketBeat
Evolus stock soars to 52-week high, hits $17.75 - Investing.com India
Evolus stock soars to 52-week high, hits $17.75 By Investing.com - Investing.com UK
Evolus Inc (EOLS) Trading 3.55% Higher on Oct 14 - GuruFocus.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 - BioSpace
Evolus Inc (EOLS) shows promising results - US Post News
(EOLS) Trading Report - Stock Traders Daily
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years - Yahoo Finance
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Millennium Management LLC - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Invests $1.33 Million in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Q3 2024 Earnings Estimate for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Trading Down 3.4%Here's Why - MarketBeat
Q4 2024 Earnings Forecast for Evolus, Inc. Issued By HC Wainwright (NASDAQ:EOLS) - MarketBeat
Evolus Bus Event - StyleBlueprint
Evolus shares hold Buy rating amid market gains By Investing.com - Investing.com Australia
Evolus shares hold Buy rating amid market gains - Investing.com
A Closer Look at 5 Analyst Recommendations For Evolus - Benzinga
HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS) - MarketBeat
Midday Stock Roundup: NKGen Biotech Plummets 35% - Orange County Business Journal
Stonepine Capital Management LLC Sells 1,016,745 Shares of Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc.'s SWOT analysis: aesthetics stock poised for growth amid challenges - Investing.com UK
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Armistice Capital LLC Acquires Shares of 360,000 Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus Defeats Investor Suit Over Botox Trade Secret Dispute - Bloomberg Law
Great Point Partners LLC Has $26.60 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - Defense World
Evolus Inc (EOLS) Shares Up 3.22% on Sep 20 - GuruFocus.com
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):